RNASET2 and Leukoencephalopathy: Although these microglial defects have not yet been described in RNAseT2‐deficient leukoencephalopathy patients, they still represent an early marker of the pathology and a potential therapeutic target for RNASET2‐deficient leukoencephalopathy.